XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Net loss $ (3,262) $ (369)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation, depletion, accretion, and amortization 4,457 264
Deferred income taxes (2,460)
Unrealized loss (gain) on commodity derivatives 4,482 170
Loss (gain) on marketable equity securities 40 (73)
Amortization of debt issuance costs 20
Loss on warrant revaluation 24
Loss on related party debt conversion and settlement of legal costs 76
Stock-based compensation 2,109 195
Right of use asset amortization 75 42
Changes in operating assets and liabilities:    
Oil and natural gas sales receivable (5,198) (208)
Other assets (192) (39)
Accounts payable and accrued liabilities 4,315 (509)
Accrued compensation and benefits (675) (125)
Payments on operating lease liability (49) (39)
Net cash provided by (used in) operating activities 3,662 (591)
Cash flows from investing activities:    
Acquisition of proved properties (4,383)
Oil and natural gas capital expenditures (1,131) (904)
Expenditures for pending acquisition (592)
Property and equipment expenditures (295) (23)
Proceeds from sale of oil and gas properties 1,231 30
Payment received on note receivable 20
Net cash used in investing activities (5,170) (877)
Cash flows from financing activities:    
Proceeds from sale of common stock, net of issuance costs 5,283
Borrowings on credit facility 4,500
Repayment of debt (3,847)
Payment of fees for credit facility (174)
Repayments of insurance premium finance note payable (236) (48)
Exercise of warrant 195
Shares withheld to settle tax withholding obligations for restricted stock awards (307) (39)
Dividend paid (578)
Net cash (used in) provided by financing activities (447) 5,196
Net (decrease) increase in cash and equivalents (1,955) 3,728
Cash and equivalents, beginning of period 4,422 2,854
Cash and equivalents, end of period $ 2,467 $ 6,582